Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014:2014:682439.
doi: 10.1155/2014/682439. Epub 2014 Jun 25.

Treatment of Vertigo: A Randomized, Double-Blind Trial Comparing Efficacy and Safety of Ginkgo biloba Extract EGb 761 and Betahistine

Larysa Sokolova  1 , Robert Hoerr  2 , Tamara Mishchenko  3
Affiliations

Treatment of Vertigo: A Randomized, Double-Blind Trial Comparing Efficacy and Safety of Ginkgo biloba Extract EGb 761 and Betahistine

Larysa Sokolova et al. Int J Otolaryngol. 2014.

Abstract

A multicenter clinical trial was performed to compare the efficacy and safety of Ginkgo biloba extract EGb 761 and betahistine at recommended doses in patients with vertigo. One hundred and sixty patients (mean age 58 years) were randomly assigned to double-blind treatment with EGb 761 (240 mg per day) or betahistine (32 mg per day) for 12 weeks. An 11-point numeric analogue scale, the Vertigo Symptom Scale-short form, the Clinical Global Impression Scales and the Sheehan Disability Scale were used as outcome measures. Both treatment groups were comparable at baseline and improved in all outcome measures during the course of treatment. There was no significant intergroup difference with regard to changes in any outcome measure. Numerically, improvements of patients receiving EGb 761 were slightly more pronounced on all scales. Clinical global impression was rated "very much improved" or "much improved" in 79% of patients treated with EGb 761 and in 70% receiving betahistine. With 27 adverse events in 19 patients, EGb 761 showed better tolerability than betahistine with 39 adverse events in 31 patients. In conclusion, the two drugs were similarly effective in the treatment of vertigo, but EGb 761 was better tolerated. This trial is registered with controlled-trials.com ISRCTN02262139.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Patient disposition and analysis sets.
Figure 2
Figure 2
Response rates, defined as clinician's global impression (CGI) rated “much improved” or “very much improved” or patient's rating of NAS improvement at least 50%.
Figure 3
Figure 3
Proportion of patients with nystagmus before and after treatment.
Figure 4
Figure 4
Proportion of patients with different grades of swaying in the Romberg test before and after treatment.
Figure 5
Figure 5
Proportion of patients with different grades of rotation in Unterberger's stepping test before and after treatment.
See this image and copyright information in PMC

References

    1. Neuhauser HK, Radtke A, von Brevern M, Lezius F, Feldmann M, Lempert T. Burden of dizziness and vertigo in the community. Archives of Internal Medicine. 2008;168(19):2118–2124. - PubMed
    1. Newman-Toker DE, Hsieh Y, Camargo CA, Jr., Pelletier AJ, Butchy GT, Edlow JA. Spectrum of dizziness visits to US emergency departments: Cross-sectional analysis from a nationally representative sample. Mayo Clinic Proceedings. 2008;83(7):765–775. - PMC - PubMed
    1. Strupp M, Brandt T. Diagnosis and treatment of vertigo and dizziness. Deutsches Ärzteblatt International. 2008;105(10):173–180. - PMC - PubMed
    1. Hanley K, O'Dowd T, Considine N. A systematic review of vertigo in primary care. British Journal of General Practice. 2001;51(469):666–671. - PMC - PubMed
    1. Okroglic S, Widmann CN, Urbach H, Scheltens P, Heneka MT. Clinical symptoms and risk factors in cerebral microangiopathy patients. PLoS ONE. 2013;8(2)e53455 - PMC - PubMed

LinkOut - more resources